Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
Intel’s Testing of China-Linked Chipmaking Tools Raises U.S. National Security Concerns 
Strategy Retains Nasdaq 100 Spot Amid Growing Scrutiny of Bitcoin Treasury Model 
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
Trello Outage Disrupts Users as Access Issues Hit Atlassian’s Work Management Platform 
Coca-Cola’s Costa Coffee Sale Faces Uncertainty as Talks With TDR Capital Hit Snag 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
SpaceX Insider Share Sale Values Company Near $800 Billion Amid IPO Speculation 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
CMOC to Acquire Equinox Gold’s Brazilian Mines in $1 Billion Deal to Expand Precious Metals Portfolio 
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
Azul Airlines Wins Court Approval for $2 Billion Debt Restructuring and New Capital Raise 
Dublin, Dec. 23, 2016 -- Research and Markets has announced the addition of the "Global Anemia Drugs Market (Iron Deficiency, Sickle Cell, CKD, Aplastic Anemia): Analysis By Region, By Country (2016-2021)" report to their offering.
Global Anemia Drugs Market is forecasted to grow at a CAGR of 9.05% during 2016-2021F, on account of rising incidences of anemia globally.
Rising development of pipeline drugs combined with the growing awareness of disease in developing countries has resulted in the growth of Anemia Drugs market. Anemia Drugs has been majorly caused due to the lack of iron intake and less iron absorption mainly among pregnant women, women of reproductive age and young children.
Among the various types of anemia, market is expected to be driven by CKD anemia, due to the growing research and development towards new biosimilars such as Hypoxia-inducible factors. However, launch of late pipeline drugs such as Rivipansel and Vepoloxamer for sickle cell anemia treatment are anticipated to drive the market in forecast period.
While developed regions will continue to dominate the market in terms of revenue, emerging nations are expected to respond to the market optimistically due to the developing healthcare infrastructure and rising focus on healthcare among the growing middle class population.
Key Topics Covered:
1. Research Methodology
2. Executive Summary
3. Strategic Recommendations
4. Global Anemia Drugs Market: An Overview
5. North America Anemia Drugs Market: An Analysis
6. Europe Anemia Drugs Market: An Analysis
7. APAC Anemia Drugs Market: An Analysis
8. Latin America Anemia Drugs Market: An Analysis
9. MEA Anemia Drugs Market: An Analysis
10. Market Dynamics
11. M&A and Licensing Route to the Anemia Drugs Treatment Market
12. SWOT Analysis
13. Porter Five Force Model
14. Company Profiling and Drug Market Potential
- Acceleron Pharma
- Akebia therapeutics
- Bayer AG
- Bluebird bio
- Celgene Corporation
- Eli Lilly
- Fibrogen
- GlaxoSmithKline
- Global Blood Therapeutics (GBT)
- GlycoMimetics
- Mast Therapeutics
- Onconova Therapeutics
- Pieris Pharmaceuticals
- Regen biopharma
For more information about this report visit http://www.researchandmarkets.com/research/7hf3md/global_anemia
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Hematological Drugs
